Sign In
Search Icon
Menu Icon

Lagevrio (molnupiravir) Frequently Asked Questions

Oral antivirals are used to treat chronic or severe viral infections that cannot be eliminated by an individual’s natural immune response. Antivirals can function in a variety of ways to treat a virus, depending on the therapy and virus type.

Lagevrio is authorized for the treatment of mild to moderate COVID-19 in adults age 18 years and older, who are at high risk for progressing to severe COVID-19 and for whom alternative COVID-19 treatment options are not accessible or clinically appropriate. Pregnant individuals or women who may become pregnant should speak with a healthcare provider regarding any treatment limitations.

Yes; a prescription from a qualified healthcare provider is required to be treated with Lagevrio.

Initial allocations were determined on a pro rata basis (based on adult population) and will be provided to state and territorial health departments for free.

A subset of HHS Health Resources Services Administration (HRSA)-funded health centers across all 50 states will also receive direct product allocation to help increase equitable access to this product in vulnerable and hard-hit communities.

Yes. State and territorial health departments can order product through the HHS Health Partners Ordering Portal. Dispensing sites began receiving product in December 2021.

A Test to Treat locator is available to help find participating sites. A call center is also available at 1-800-232-0233 (TTY 1-888-720-7489) to get help in English, Spanish, and more than 150 other languages – 8:00 am to midnight ET, 7 days a week. The Disability Information and Access Line (DIAL) is also available to specifically help people with disabilities access services. To get help, call 1-888-677-1199, Monday-Friday from 9:00 am to 8:00 pm ET or email

​ ​